Infant

Dairy Council of California Releases Culturally Responsive Nutrition Resource for the Hispanic Community

Retrieved on: 
Wednesday, March 6, 2024
Social media, National Association, Dairy Council of California, Life, Reduction, Infant, Continuity, United, Birth control

SACRAMENTO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, announced the release of a culturally responsive resource to support infant and toddler nutrition for Hispanic families.

Key Points: 
  • SACRAMENTO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, announced the release of a culturally responsive resource to support infant and toddler nutrition for Hispanic families.
  • Collaborating with dietitians and nutritionists that work with the Hispanic community, Dairy Council of California served as lead consultant to coordinate development of the critical resource.
  • This resource provides an actionable way to better reach families with culturally tailored nutrition resources that are relevant and relatable.
  • The community’s feedback on the resource has been very positive,” states Dairy Council of California CEO Amy DeLisio.

Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis

Retrieved on: 
Tuesday, March 5, 2024
Food, Diabetes, Fungus, Tiny, General partnership, Physician, Obesity, Pediatrics, Asthma, Overalls, Parent, Parasitism, Allergy, Life, Risk, IRB, Constipation, Health, Bacteria, Virus, Mother, Infant, Dermatitis, ADHD, Child, Science, Archaea, Research, Immune system, Partnership, Birth control

The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.

Key Points: 
  • The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.
  • Families are facing a pediatric chronic conditions crisis, with increasing rates of eczema, asthma, diabetes, obesity, food allergies, ADHD, autoimmune diseases, and more.
  • I founded Tiny Health to bridge the gap in the market, help address the pediatric chronic conditions crisis, and empower families to take a proactive approach to their lifelong health.
  • Since its inception, Tiny Health has pioneered the family gut testing category including:
    Established the first, at-home gut microbiome test for babies.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business

Retrieved on: 
Friday, February 23, 2024
Litre, Arrangement, Health Canada, OBG, TSX, Data monitoring committee, LDL, MBA, Assay, Safety, Cheese, University, Food engineering, University of Alberta, CZO, Infant, NPN, Journal, Protein, Clinical trial, Whey, Canada Business Corporations Act, Tissue, Water, Dietary supplement

EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.

Key Points: 
  • EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business.
  • In addition to the proposed Arrangement, the Company continues to execute on progress across its ongoing development projects, as detailed below.
  • “We continue to make promising progress across all areas of our business.
  • Given the recent developments, we anticipate that all key success factors will align to expand our business model.

Calgary Health Foundation Receives Funds to Ensure Seamless Care in NICU Environments

Retrieved on: 
Thursday, February 22, 2024
Hospital, Intensive care unit, Foothills Medical Centre, Research, Infant, Patient, NICU

This funding helps to ensure the SANTS team is equipped with the same technology as the NICU, to provide consistent monitoring and seamless transfer between the care environments.

Key Points: 
  • This funding helps to ensure the SANTS team is equipped with the same technology as the NICU, to provide consistent monitoring and seamless transfer between the care environments.
  • “Through donations and collaborations like this, we are able to continue to offer world-class care and ensure a promising future for our smallest patients and their families.
  • “You don’t realize how valuable all those donations are until you’re sitting in the NICU looking at all the equipment.
  • In each of the last three years, thanks to generous supporters, the Foundation has donated $1 million for lifesaving equipment for babies.

Study: Prenatal COVID exposure associated with changes in newborn brain

Retrieved on: 
Thursday, February 22, 2024
Cortex, Paper, Oxygen, Anxiety, Nursing, Infection, Coronavirus, Magnetic resonance imaging, Inflammation, Neuron, Fetus, Schizophrenia, Hospital, Pregnancy, Learning, Life, Radiation, Risk, Human, COVID-19, Frontal lobe, Walking, Virus, Health, Mother, COVID, Infant, Patient, Depression, Attention deficit hyperactivity disorder, News, Child, Fungal infection, Spectrum, Placenta, Research, MRI, Brain, Medical imaging

The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.

Key Points: 
  • The findings suggest that exposure to the coronavirus and being pregnant during the pandemic could play a role in shaping infant brain development, said Nickie Andescavage, M.D.
  • In contrast, an inner area of the brain, known as deep gray matter, was smaller than in unexposed babies.
  • “Their brains formed differently if they were exposed to COVID,” said Dr. Andescavage, adding that “those exposed to COVID had unique signatures” in the brain.
  • But other studies have linked maternal stress and depression to changes in the newborn brain .

Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Retrieved on: 
Wednesday, February 21, 2024
Mental health, Woman, PNP, Suicide, Infection, Prenatal development, Hospital, Public health, Bleeding, MPA, Fatality, Maternal death, Mental, DSM-IV codes, Pregnancy, Communication, Death, Internal bleeding, Risk, Health, JAMA Psychiatry, FACOG, University, Infant, Disease, Mother, White, Health policy, Maternal health, Child, Mortality, Drug overdose, George Washington University, Research, Medicine, Depression

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.

Key Points: 
  • “The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.
  • , associate chief of Perinatal Mental Health and member of the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National.
  • Overdose and other maternal mental health conditions are taking the lives of more than twice as many women as postpartum hemorrhage, the second leading cause of maternal death.
  • Mental health conditions such as suicide or opioid overdose are to blame for nearly 23% of maternal deaths in America, according to reports from three dozen Maternal Morbidity and Mortality Review Committees, which are state-based organizations that review each maternal death within a year of pregnancy.

Owlet Announces Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
Apps, Applications, Mobile, Wireless, Technology, Parenting, Baby, Maternity, Specialty, Software, Consumer, Retail, Consumer Electronics, Operating cost, OWLT, FDA, Adjustment, Entrepreneurship, Babysitting, Infant, Net, FY, Cryptocurrency

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • I’m proud of the immense progress our team has made in re-shaping the Company in 2023, and I look forward to continued successes in 2024.”
    Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Revenues for the fourth quarter of 2023 were approximately $21.0 million.
  • Adjusted EBITDA loss was approximately $0.7 million for the fourth quarter of 2023, compared to $15.2 million for the fourth quarter of 2022.
  • Net loss per share was $0.97 for the fourth quarter of 2023, compared to net loss per share of $2.43 for the fourth quarter of 2022.

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Wednesday, March 6, 2024
Health, Genetics, Other Science, General Health, Science, Pharmaceutical, Biotechnology, Liver, Parkinson's disease, Pet, Movement disorder, Annual report, Marketing, Investment, WalletHub, ChromaDex, Growth, Conference, Biomarker, GAAP, Tru, Replay, History, NAD, Infant, Patient, Optimism, Webcast, Clinical trial, Security (finance), Nature Communications, Longevity, Heart, Brain, Research, Partnership, Pharmaceutical industry

ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2023 financial results.
  • Maintained positive operating cash flows for a fourth consecutive quarter, ending with $27.3 million in cash and no debt.
  • Additionally, the fourth quarter marked an important milestone with the company achieving positive net income,” said Rob Fried, ChromaDex Chief Executive Officer.
  • ChromaDex ended fiscal year 2023 with $27.3 million in cash and cash equivalents and no debt.

Global Wearable Breast Pump Market Size, Share & Trends Analysis Report 2024: Now Available - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 6, 2024
Retail, Specialty, Baby, Maternity, Consumer, Woman, USD, Sun Pharma, Growth, Parent, Death, COVID-19, Mother, Infant, Employment, JPMorgan Chase, Statistics Canada, Mortality, Component

The "Global Wearable Breast Pump Market Size, Share & Trends Analysis Report by Component (Wearable Pumps, Accessories), Technology (Battery Powered Pumps, Smart Pumps, Manual Pumps), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Wearable Breast Pump Market Size, Share & Trends Analysis Report by Component (Wearable Pumps, Accessories), Technology (Battery Powered Pumps, Smart Pumps, Manual Pumps), Region, and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global wearable breast pump market is estimated to reach USD 975.47 million by 2030, growing at a CAGR of 8.55%
    Favorable reimbursement policies, and increasing patient disposable income are further anticipated to propel the demand for wearable breast pumps.
  • Such instances are expected to increase the demand for wearable breast pumps, thereby propelling the market growth over the forecast period.
  • This will surge the need for wearable breast pumps for working women, thereby propelling the market growth in post COVID-19 time.